In‑vivo CAR‑T reads out: Kelonia posts early multiple myeloma signals

Kelonia Therapeutics reported initial in‑vivo CAR‑T data showing tumor clearance in early multiple myeloma patients, boosting interest in systemically delivered CAR modalities that program T cells inside the body. The company’s readouts—presented at ASH and summarized in follow‑up reports—demonstrated proof of concept for a single‑infusion approach intended to avoid complex ex vivo manufacturing. In‑vivo CAR‑T refers to strategies that deliver genetic payloads or vectors directly to patients to generate therapeutic T cells internally, potentially simplifying logistics and cost.